Phase 3 N=143 Behavioral Treatment of Overactive Bladder in Men
Overactive Bladder
Primary: 24-hour Voiding Frequency — 9.1; 9.5 voids per 24-hour day — p=.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=60 Urinary Cytokines in Patients With Overactive Bladder (OAB)
Overactive Bladder · Urinary Tract Infection
Primary: Number of Participants With Elevated Cytokines (Levels of Pro-inflammatory) — 20; 20; 16 Participants
Phase 4 N=254 OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With Overactive Bladder
Overactive Bladder
Primary: Percentage of Participants Who Achieve a 100% Reduction in Urinary Incontinence Episodes — 32.0; 7.2 percentage of participants
Phase 4 N=70 The Efficacy of Solifenacin With or Without Tamsulosin in Adult Women With Overactive Bladder (OAB)
Overactive Bladder
Primary: Change in Mean Number of Micturition Episodes Per 24 Hours — -1.9; -2.2 episodes
N/A N=20 Hypnotherapy for Treatment of Overactive Bladder
Overactive Bladder
Primary: Change in Overactive Bladder Symptoms (Based on OABqSF) — -19; -33.4 units on a scale — p=.07
Phase 3 N=356 A Study Evaluating the Efficacy and Safety of BOTOX® or Solifenacin in Patients With Overactive Bladder and Urinary Incontinence
Overactive Bladder · Urinary Incontinence
Primary: Change From Study Baseline in Number of Episodes of Urinary Incontinence in Treatment Cycle 1 — 4.86; 5.23; 4.38; -3.10 Incontinence Episodes
Phase 3 N=248 Efficacy and Safety of GSK1358820 in Subjects With Overactive Bladder
Urinary Bladder, Overactive
Primary: Treatment Phase 1 (Treatment Cycle 1): Change From Baseline in the Daily Average Number of Urinary Incontinence Episodes at Week 12 After the First Treatment — -1.25…
Phase 4 N=127 Trospium Chloride XR in Obese Female Patients With Overactive Bladder
Obesity · Overactive Bladder · Incontinence
Primary: Percent Change From Baseline in Urinary Urgency Incontinence (UUI) — -23.7; 57.8 Percent change
Phase 3 N=204 Combined Behavioral and Drug Treatment of Overactive Bladder in Men
Overactive Bladder · Lower Urinary Tract Symptoms
Primary: Change in Frequency of Urination After 6-week Intervention (Last Observation Carried Forward) — 2.7; 1.5; 3.3 voids per day — p=<.0001
Phase 4 N=23 Treatment of Incontinence Without Memory Problems
Urge Incontinence · Urinary Incontinence, Urge
Primary: The Number of Participants Who Completed and Discontinued the Study — 11; 10; 1; 1 Participants — p=0.949
Phase 3 N=516 A Clinical Trial To Assess Fesoterodine On Treatment Satisfaction And Symptom Improvement In Overactive Bladder Patients
Overactive Bladder
Primary: Mean Number of Micturition Episodes Per 24 Hours — 12.7; 9.7 number of episodes — p=<0.0001
Phase 3 N=249 Anticholinergic vs. Botox Comparison Study
Urge Urinary Incontinence · Overactive Bladder
Primary: Change in Urge Urinary Incontinence (UUI) Episodes — -3.13; -3.15; -3.32; -3.25 Mean change in UUI episodes from baselin
Phase 2 N=550 SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS)
Overactive Bladder Syndrome (OABS)
Primary: Change From Baseline to Week 8 in the Number of Voids/24 Hours — -1.06; -1.44; -1.78; -2.41 voids/24 hrs.
Phase 3 N=548 Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence
Overactive Bladder
Primary: Change From Baseline in Number of Daily Episodes of Urinary Incontinence — 5.52; 5.70; -2.95; -1.03 Incontinence episodes
Phase 4 N=23 Solifenacin Succinate (VESIcare) for the Treatment of Overactive Bladder in Parkinson's Disease
Overactive Bladder in Parkinson's Disease
Primary: Number of Micturations Per 24 Hour Period — 8.78; 9.19; 8.00; 8.94 Number of micturations per 24 hours — p=0.53
Phase 3 N=30 Botox for the Treatment of Overactive Bladder Secondary to Benign Prostatic Obstruction
Overactive Bladder
Primary: Urinary Frequency — 10.5; 11; 12; 8.5 urinations
Phase 2 N=80 URO-902 in Female Subjects With Overactive Bladder and Urge Urinary Incontinence
Overactive Bladder With Urge Urinary Incontinence
Primary: Change From Baseline at Week 12 in Average Daily Number of Urgency Episodes — -1.13; -2.43; -3.37 Urgency episodes per day — p==0.1722
Phase 3 N=189 A Study to Investigate How Effective and Safe Solifenacin Succinate Suspension is in Treating Children/Adolescents Aged 5 to Less Than 18 Years With Symptoms of Overactive Bladder (OAB) Compared to a Non-active Drug
Urinary Bladder, Overactive
Primary: Change From Baseline to End of Treatment (EoT) in Mean Volume Voided (MVV) Per Micturition — 13.4; 25.5; 6.9; 2.3 mL — p=0.046
Phase 4 N=100 Overactive Bladder Innovative Therapy Trial (OrBIT)
Overactive Bladder
Primary: Frequency of Voids at 12 Weeks — -2.4; -2.5 Voids/day
Phase 4 N=120 Evaluation of an Alternative Injection Paradigm for OnabotulinumtoxinA (BOTOX®) in the Treatment of Overactive Bladder in Patients With Urinary Incontinence
Urinary Bladder, Overactive · Urinary Incontinence
Primary: Change From Baseline in Daily Average Number of Urinary Incontinence Episodes — -2.99; -0.42 incontinence episodes per day — p=<.0001
Phase 3 N=2,174 A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)
Urinary Bladder Diseases · Urinary Bladder Overactive · Urologic Diseases
Primary: Change From Baseline to End of Treatment (EoT) in Mean Number of Incontinence Episodes Per 24 Hours — -1.8; -1.53; -1.67 incontinence episodes — p==0.001
Phase 2 N=313 A Research Study for Patients With Overactive Bladder
Overactive Bladder · Urinary Incontinence
Primary: Change in Number of Urinary Urge Incontinence Episodes — 32.5; 30.3; 27.8; 28.3 episodes
N/A N=823 Study In Patients With Overactive Bladder Treated With Toviaz® After Failure Of Previous Therapy
Overactive Bladder · Urinary Incontinence
Primary: Change From Baseline in Micturition Frequency Per 24 Hours at Each Visit — 11.661; 10.636; 12.664; -2.306 episodes
N/A N=150 The Effect of Urox™ in the Treatment of Overactive Bladder and Urinary Incontinence
Overactive Bladder · Urinary Incontinence · Urinary Frequency or Urgency Adverse Event
Primary: Day Urinary Frequency — 7.68; 10.95 number of diurnal micturitions per day
Phase 4 N=24 A Study Evaluating Oxybutynin in Patients With Neurogenic Overactive Bladder Associated With a Neurological Condition
Detrusor Hyperreflexia
Primary: Average Number of Catheterizations Without Leaking Per Day — 2.4; 1.5 Number of Dry Catheterizations per Day
Phase 4 N=54 Posterior Tibial Nerve Stimulation (PTNS) Plus Mirabegron to Treat Refractory OAB Symptoms (PTNS-M Study)
Overactive Bladder
Primary: Change in the Number of UUI Episodes Over a 3-day Voiding Diary Pre- vs. Post-treatment. This Includes a Baseline Measure Pre-trial and a Pos-trial Measure in 12 Weeks…
Phase 4 N=376 A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB)
Overactive Bladder (OAB)
Primary: Participants Tolerability Assessed by the Medication Tolerability Scale of the Overactive Bladder-Satisfaction (OAB-S) Questionnaire at the End of Treatment (EOT)…
Phase 2 N=106 Interventional Clinical Trial in Patients in Overactive Bladder With Nocturia in Women
Overactive Bladder
Primary: Change in Mean Number of Nocturnal Voids From Baseline — -1.63; -1.29 Voids — p=0.112
Phase 4 N=147 InSite for Over Active Bladder
Urinary Incontinence, Urgency-frequency · Overactive Bladder
Primary: Randomized Cohort: OAB Therapeutic Response — 61; 42 percentage of participants with response — p=0.016
Phase 2 N=62 Effects and Safety of Liposome Encapsulated Botulinum Toxin A for Overactive Bladder Syndrome
Overactive Bladder
Primary: Mean Change of the Total Frequency Per 3 Days — -4.64; -0.19 Frequency per 3 days